Profile data is unavailable for this security.
About the company
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
- Revenue in USD (TTM)131.00k
- Net income in USD-34.50m
- Incorporated2015
- Employees11.00
- LocationINmune Bio Inc225 Ne Mizner Blvd, Suite 640BOCA RATON 33432United StatesUSA
- Phone+1 (858) 964-3720
- Websitehttp://www.inmunebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galectin Therapeutics Inc | 0.00 | -44.78m | 144.81m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
| Metagenomi Inc | -100.00bn | -100.00bn | 145.36m | 237.00 | -- | 0.5274 | -- | -- | -- | -- | -- | 7.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 145.45m | 65.00 | -- | 1.40 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 148.12m | 158.00 | -- | 0.4315 | -- | 4.43 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Puma Biotechnology Inc | 226.63m | 15.38m | 149.06m | 185.00 | 9.60 | 2.92 | 5.54 | 0.6577 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 149.37m | 459.00 | -- | -- | -- | 1.45 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 150.80m | 29.00 | -- | 1.88 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 151.50m | 5.00 | -- | 3.82 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| INmune Bio Inc | 131.00k | -34.50m | 152.32m | 11.00 | -- | 4.76 | -- | 1,162.78 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 153.97m | 101.00 | -- | 8.30 | -- | 5.68 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 154.08m | 179.00 | -- | 0.6585 | -- | 1.57 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Compass Therapeutics Inc. | 0.00 | -45.44m | 154.10m | 32.00 | -- | 0.9812 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 155.35m | 112.00 | -- | -- | -- | 7.07 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Alpha Tau Medical Ltd | 0.00 | -28.95m | 155.65m | 121.00 | -- | 1.97 | -- | -- | -0.4165 | -0.4165 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -26.50 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.0653 | -- | -- | -- | 13.64 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 158.34m | 147.00 | -- | -- | -- | 1.32 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Alimera Sciences Inc | 90.22m | -22.66m | 159.79m | 159.00 | -- | 3.93 | -- | 1.77 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
Data as of Jun 18 2024. Currency figures normalised to INmune Bio Inc's reporting currency: US Dollar USD
9.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 536.79k | 2.71% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 233.87k | 1.18% |
| MAI Capital Management LLCas of 31 Mar 2024 | 181.41k | 0.92% |
| Rhenman & Partners Asset Management ABas of 31 Mar 2024 | 178.28k | 0.90% |
| Geode Capital Management LLCas of 31 Mar 2024 | 170.80k | 0.86% |
| Millennium Management LLCas of 31 Mar 2024 | 159.19k | 0.81% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 154.83k | 0.78% |
| Janney Montgomery Scott LLC (Investment Management)as of 31 Mar 2024 | 140.91k | 0.71% |
| DWS Investment GmbHas of 31 Mar 2024 | 109.85k | 0.56% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 87.61k | 0.44% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
